Analysts rate Merck a buy based on its track record of consistent earnings growth and robust cash generation. Over the past twelve months, the company delivered double-digit year-over-year EBITDA growth—outpacing all major peers—and generated $17.1 billion in operating cash flow. Free cash flow has risen by 14% year-over-year, allowing management to maintain a 15-year dividend growth streak and repurchase $8 billion of shares in the last fiscal year. Merck’s debt-to-EBITDA ratio sits at 1.5x, reflecting balance sheet strength that supports continued investment in R&D and shareholder returns.

Keytruda remains the cornerstone of Merck’s growth profile, contributing over 30% of total revenue and achieving double-digit sales growth for the ninth consecutive quarter. Improved manufacturing efficiencies and scale have expanded Keytruda’s operating margin from 54% to 58% over the past year, translating into a 250 basis-point lift in overall corporate profitability. Despite patent exclusivity expiring in 2028, Merck is preparing for a subcutaneous formulation launch under the QLEX program, which could extend effective market protection by an additional 12–18 months and support sustained cash flow generation during the transition.

Merck trades at 13.8x forward P/E—the lowest among large-cap pharmaceutical peers—and carries a PEG ratio of 1.23, signaling an attractive entry point for value-oriented investors. Market concerns over the 2028 patent cliff obscure the strength of the broader pipeline, which includes Winrevair (near-term sales approaching $1 billion) and Capvaxive (projected peak sales exceeding $2 billion). With $18.2 billion in cash and equivalents on the balance sheet, Merck is well positioned to fund late-stage programs and pursue strategic bolt-on acquisitions to offset future revenue declines.